157 related articles for article (PubMed ID: 33337316)
1. The Impact of Prescription Medication Cost Coverage on Oral Medication Use for Hypertension and Type 2 Diabetes Mellitus.
Amoud R; Grindrod K; Cooke M; Alsabbagh MW
Healthc Policy; 2020 Nov; 16(2):82-100. PubMed ID: 33337316
[TBL] [Abstract][Full Text] [Related]
2. Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high blood cholesterol.
Iyengar RN; Balagere DS; Henderson RR; LeFrancois AL; Rabbitt RM; Frazee SG
J Manag Care Spec Pharm; 2014 Aug; 20(8):851-61. PubMed ID: 25062079
[TBL] [Abstract][Full Text] [Related]
3. Impact of drug plans on adherence to and the cost of antihypertensive medications among patients covered by a universal drug insurance program.
Després F; Perreault S; Lalonde L; Forget A; Kettani FZ; Blais L
Can J Cardiol; 2014 May; 30(5):560-7. PubMed ID: 24613090
[TBL] [Abstract][Full Text] [Related]
4. Impact of type 2 diabetes mellitus on prescription medication burden and out-of-pocket healthcare expenses.
Rodbard HW; Green AJ; Fox KM; Grandy S;
Diabetes Res Clin Pract; 2010 Mar; 87(3):360-5. PubMed ID: 20047768
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
Pauly NJ; Brown JD
J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
[TBL] [Abstract][Full Text] [Related]
6. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
7. Inequity in insurance coverage for prescription drugs in New Brunswick, Canada.
Ayodele B; Guo EX; Sweetman A; Guindon GE
Can J Public Health; 2022 Aug; 113(4):504-518. PubMed ID: 35488147
[TBL] [Abstract][Full Text] [Related]
8. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
Kennedy J; Morgan S
Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
[TBL] [Abstract][Full Text] [Related]
9. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Private Insurance Coverage on Prescription Drug Use in Ontario, Canada.
Kratzer J; Cheng L; Allin S; Law MR
Healthc Policy; 2015 May; 10(4):62-74. PubMed ID: 26142359
[TBL] [Abstract][Full Text] [Related]
11. Is patients' insurance coverage associated with prescribing after hospitalization for severe, poorly controlled hypertension?
Dy SM; Klag MJ; Young JH
J Clin Hypertens (Greenwich); 2008 Sep; 10(9):684-91. PubMed ID: 18844763
[TBL] [Abstract][Full Text] [Related]
12. A pilot study on cost-related medication nonadherence in Ontario.
Zheng B; Poulose A; Fulford M; Holbrook A
J Popul Ther Clin Pharmacol; 2012; 19(2):e239-47. PubMed ID: 22805096
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Dual Health Care System Use for Obtaining Prescription Medications on Nonadherence in Veterans With Type 2 Diabetes.
Taber DJ; Ward R; Axon RN; Walker RJ; Egede LE; Gebregziabher M
Ann Pharmacother; 2019 Jul; 53(7):675-682. PubMed ID: 30724092
[TBL] [Abstract][Full Text] [Related]
14. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia.
Li P; McElligott S; Bergquist H; Schwartz JS; Doshi JA
Ann Intern Med; 2012 Jun; 156(11):776-84, W-263, W-264, W-265, W-266, W-267, W-268, W-269. PubMed ID: 22665815
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?
Sacks NC; Burgess JF; Cabral HJ; McDonnell ME; Pizer SD
J Manag Care Spec Pharm; 2015 Aug; 21(8):678-87. PubMed ID: 26233540
[TBL] [Abstract][Full Text] [Related]
16. Impact of a value-based formulary in three chronic disease cohorts.
Yeung K; Basu A; Marcum ZA; Watkins JB; Sullivan SD
Am J Manag Care; 2017 Mar; 23(3 Suppl):S46-S53. PubMed ID: 29648740
[TBL] [Abstract][Full Text] [Related]
17. Measuring medication adherence in patients with incident hypertension: a retrospective cohort study.
Tang KL; Quan H; Rabi DM
BMC Health Serv Res; 2017 Feb; 17(1):135. PubMed ID: 28193217
[TBL] [Abstract][Full Text] [Related]
18. The effect of cost on adherence to prescription medications in Canada.
Law MR; Cheng L; Dhalla IA; Heard D; Morgan SG
CMAJ; 2012 Feb; 184(3):297-302. PubMed ID: 22249979
[TBL] [Abstract][Full Text] [Related]
19. Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence.
Amin K; Farley JF; Maciejewski ML; Domino ME
J Manag Care Spec Pharm; 2017 Mar; 23(3):337-345. PubMed ID: 28230447
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Reduced Drug Copayments on Adherence to Oral Diabetes Medications Among Childless Adults in Wisconsin Medicaid.
Kim NH; Look KA
J Manag Care Spec Pharm; 2019 Dec; 25(12):1432-1441. PubMed ID: 31778619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
